Figure 2

Survival analysis of BRCA1/2 mutation carriers (A) and non carriers (B) according to their MDM2 SNP type. SNP309 G/G carriers were compared to the combined group of SNP309 G/T and SNP309 T/T. In the BRCA carrier group there were 41 G/G patients of whom 7 died (median survival 412 months) while in the combined SNP309 G/T and T/T group there were 126 patients of whom 35 died (median survival 301 months). According to a log-rank test the significance of the difference in survival was P = 0.0086. In the control group the survival for the MDM2 SNP309 G/G carriers was was not statistically different (p = 0.8).